Barclays Reiterates Overweight Rating on Oracle (February)
- Rating
- Overweight
- Unchanged
- Target
- $310
- Upside
- +169%
- ORCL at $115 today

What the analyst said
Barclays analyst Raimo Lenschow reiterated an Overweight rating and $310.00 price target on Oracle (NYSE: ORCL).
“We see ORCL shares higher post the proposed raise of $45-50bn (approx. 1/2 through equity/equity-linked issuances) of gross cash proceeds.
The transactions alleviate pressure for the credit story (incl. maintaining its IG rating) and gives clarity about the financing needs for the year.”
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.
This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.
Where the price stands
ORCL trades at $115. The 22 analysts who set a target in the last 3 months range from $155 to $400, with a median of $233. This $310 target is 33% above the median.
Since the note ORCL has moved −30% (from $165). 12-month window: day 276 of 365, closes on February 2, 2027.
Track record
This callOpen: ORCL has not reached $310 yet. This 12-month target is scored on February 2, 2027.
Firm track recordBarclays: 83% of its 40 targets at least a year old were reached within 12 months (#7 of 26 firms). Accuracy ranking →
Barclays on Oracle
Barclays price targets on Oracle
6 calls from February 2, 2026 to September 11, 2026. The target went from $310 to $252 (−19%). The rating stayed Buy.




